TAILIEUCHUNG - Checkpoint inhibitors in metastatic gastric and GEJ cancer: A multi-institutional retrospective analysis of real-world data in a Western cohort

Safety and efficacy of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction (GEJ) cancer could be demonstrated in predominantly Asian cohorts, whereas data in Western patients outside of clinical trials are vastly missing. | Schlintl et al. BMC Cancer 2022 22 51 https s12885-021-09115-6 RESEARCH ARTICLE Open Access Checkpoint inhibitors in metastatic gastric and GEJ cancer a multi-institutional retrospective analysis of real-world data in a Western cohort Verena Schlintl1 Florian Huemer1 Gabriel Rinnerthaler1 Thomas Melchardt1 Thomas Winder2 Patrick Reimann2 Jakob Riedl3 Arno Amann4 Wolfgang Eisterer5 Franz Romeder6 Gudrun Piringer7 Aysegül Ilhan Mutlu8 Ewald Wöll9 Richard Greil1 and Lukas Weiss1 Abstract Background Safety and efficacy of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction GEJ cancer could be demonstrated in predominantly Asian cohorts whereas data in Western patients outside of clinical trials are vastly missing. Methods In this multi-institutional retrospective analysis conducted at nine oncologic centers in Austria we tried to assess feasibility of checkpoint inhibitors in advanced gastric GEJ cancer in a real-world Western cohort. Results In total data from 50 patients with metastatic gastric GEJ cancer who received nivolumab or pembroli zumab in a palliative setting between November 2015 and April 2020 have been evaluated. The median number of previous palliative therapy lines was two. The median progression-free survival PFS and overall survival OS were 95 CI and 95 CI months respectively. There was no statistically significant difference in median OS according to microsatellite or PD-L1 status. However a trend towards prolonged PFS and OS for the micro satellite instability high subgroup could be observed. Patients with an ECOG Performance Status PS 2 displayed a significantly worse outcome than those with an ECOG PS 1 p .03 . Only one patient discontinued immunother apy due to treatment-related toxicity. Conclusions Our results support feasibility of nivolumab and pembrolizumab in pre-treated patients with meta static gastric and GEJ cancer in a Western real-world cohort. Further phase II III .

• Y khoa - Dược
• BMC Cancer
• Gastric cancer
• Gastroesophageal junction
• Immune checkpoint inhibitors
• Treatment related toxicity
• Progression free survival
• Cancer patient pathways
• Colorectal cancer
• Lung cancer
• Breast cancer
• Prostate cancer
• Ovarian cancer
• Cancer detection
• Ovarian cancer symptoms
• Ovarian cancer signs
• Ovarian cancer tests
• Cancer biomarkers
• Pediatric cancer
• Familial cancer predisposition
• Hereditary cancer syndrome
• Genetic cancer susceptibility
• Advanced cancer
• Biliary tract cancer
• Multimodal intervention
• Pancreatic cancer
• Physical activity
• Breast cancer screening
• Familial breast cancer
• Young breast cancer survivors
• High risk relatives
• Randomized trial
• Childhood cancer
• Childhood cancer survivor
• Thyroid cancer screening
• Secondary cancer
• Cancer screening
• Community awareness
• Cancer education
• Cervical cancer
• Prior cancer
• Cancer survivors
• Cancer registry
• Second cancer
• Surgical oncology
• Cancer imaging
• Radiation oncologists
• Medical oncologists
• Oesophagogastric cancer
• Liver cancer
• Hepatobiliary cancer
• Multidisciplinary rehabilitation
• EGFR mutation
• Family history of cancer
• Inherited susceptibility
• Cancer predisposition genes
• Lung cancer aetiology
• Cancer stem cells
• Oct4 overexpressing lung cancer
• Human lung cancer xenograft model
• Disease free survivals
• Cancer hallmarks
• Cancer genesis
• Defiant disease
• Mutational signature
• Cancer diagnosis
• Cancer genomics
• Molecular medicine
• Whole genome sequencing
• Cancer susceptibility gene
• Breast cancer prognosis
• Next generation sequencing
• Quality of care
• Quality indicators
• Shifting cancer care
• German cancer society
• Colorectal cancer screening
• Stomach cancer screening
• Lung cancer survivor
• Physician recommendation
• Total number of lymph nodes
• Lymph node ratio
• Left colon cancer
• Right colon cancer
• Overall survival
• Cumulative incidence
• Esophageal cancer
• Head and neck cancer
• Metachronous cancer
• Young onset
• Reproductive cancer
• Risk factor
• Early detection of cancer
• Gastric cancer incidence
• Population based specialized registry
• Gastric cancer survival
• Gastric cancer clinical characteristics
• Gastric cancer pathological characteristics
• Lung Cancer Screening
• Racial disparities
• Lung Cancer diagnosis
• Screening adherence
• Second primary colorectal cancer
• Standardized incidence ratio
• Left sided colon cancer
• Right sided colon cancer
• Quality of cancer care
• Population based study